We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Global PCR Market to Surpass USD 7 Billion by 2025

By LabMedica International staff writers
Posted on 03 May 2018
Print article
The global polymerase chain reaction market (PCR) was valued at USD 3.7 billion in 2017 and is projected to grow at a CAGR of 8.8% over the forecast period (2017 – 2025) to surpass USD 7.4 billion by 2025. The extensive applications of the PCR laboratory technique in various fields, rising prevalence and incidence of infectious and chronic diseases, and growing need to develop advanced PCR systems for the rapid and inexpensive quantitative detection of target samples are expected to be the key growth drivers of the PCR market during the forecast period.

These are the latest findings of Coherent Market Insights (Seattle, WA, USA), a market research and consulting firm.

Based on product type, reagents and consumables hold the largest share of the PCR market due to the need to run the sample and amplify the target DNA sequence in PCR instruments. Based on end-user, academic and research laboratories account for the largest market share, on account of the increasing need for PCR systems in advanced laboratory testing and research services.

The use of PCR is increasing in the clinical diagnosis of infectious disease, nucleic acid amplification, paternity testing, DNA fingerprinting, detection and diagnosis of infectious disease, quality control, and personalized medicine. However, R&D advancements are resulting in the creation of various alternative nucleic acid amplification methods, such as loop medicated isothermal amplification, nucleic acid sequence based amplification, strand displacement amplification, and multiple displacement amplification. These methods offer better applicability and sensitivity in nucleic acid amplification, as compared to PCR, which has limitations such as contamination, sensitivity to certain classes of contaminants and inhibitors, and requirement of thermal cycling. These alternative nucleic acid amplification methods could hamper the growth of the PCR market during the forecasted period.

The key players in the PCR market offer PCR-free nucleic acid detection methods. They are also launching advanced and novel PCR instruments and consumables, which allow for rapid and easy nucleic acid amplification. Additionally, these key players have entered into a number of collaborations to expand their geographical reach and increase patient reach. Thus, the significant organic and inorganic growth strategies adopted by various key players is driving the growth of the PCR market. Geographically, there is growing demand for continuous technological advancements in PCR from the highly lucrative markets, particularly Asia Pacific, Latin America, the Middle East, and Africa.

Related Links:
Coherent Market Insights

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.